Clinical study to investigate safety and efficacy on autologous tumor lysate-pulsed dendritic cells

Clinical study to investigate safety and efficacy on autologous tumor lysate-pulsed dendritic cells - Clinical study to investigate safety and efficacy on autologous tumor lysate-pulsed dendritic cells

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000001903

Enrollment

Registered

2009-05-01

Start date

2009-05-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Malignant Glioma

Interventions

Tumor lysate-pulsed dendritic cell temozolomide

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Malignant Glioma patients who have: 1)Measurable lesion or after surgical resection of recurrent lesion. 2)Patient's tumor tissue. 3)20 years or more. 4)More than 3 months since prior external beam radiotherapy. 5)No serious abnormality in bone marrow. liver and/or renal functions.

Exclusion criteria

Exclusion criteria: 1)Pulmonary fibrosis or interstitial pneumonia, or their history, or predisposition to them 2)Serious drug allergy 3)Positive for hepatitis B, C, HIV-1, 2, HTLV-1 or syphilis 4)Serious cardiac disease 5)Active autoimmune diseases 6)Other cancers 7)Uncontrollable infection 8)Pregnancy or lactation 9)Gelling of plasma, cryogloblinemia 10)Any reason why, in the opinion of the investigator, the patient should not participate

Design outcomes

Primary

Measure	Time frame
Safety	—

Secondary

Measure	Time frame
Antitumor effect Progression-free survival Overall survival QOL Immunological responses	—

Countries

Japan

Contacts

Public ContactYonehiro Kanemura

Osaka National Hospital, National Hospital Organization Institute for Clinical Research

gliomadc@onh.go.jp

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026